肺部疾病是全球范围内威胁人类健康的主要疾病之一，肺部疾病的临床治疗药物包括止咳祛痰药、支气管扩张剂、抗纤维化药物、糖皮质激素、化疗药物、靶向药物、生物制剂等。羟基红花黄色素A可通过减轻炎症反应、减轻气道高反应性、减轻氧化应激反应、阻止肺纤维化、抗肺癌对多种肺部疾病发挥治疗作用。总结了羟基红花黄色素A防治肺部疾病的药理作用研究进展，为羟基红花黄色素A的临床应用提供参考。

Pulmonary diseases are one of the major threats to human health worldwide. Clinical treatment drugs for pulmonary diseases include cough suppressants, bronchodilators, anti-fibrotic drugs, glucocorticoids, chemotherapy drugs, targeted drugs, biologics, etc. Hydroxysafflor yellow A can exert therapeutic effects on various pulmonary diseases by reducing inflammation response, airway hyperresponsiveness, oxidative stress response, preventing pulmonary fibrosis, and anti-lung cancer. This article summarizes the pharmacological research progress of hydroxysafflor yellow A in preventing and treating pulmonary diseases, providing reference for the clinical application of hydroxysafflor yellow A.

R285.5;R974

攀枝花市指导性科技计划（2024ZD-S-122）